HYBRID ANNULOPLASTY RING FOR TRICUSPID OR MITRAL VALVE REPAIR

Abstract

An annuloplasty ring prosthesis comprising a frame having an outer surface; and a cover surrounding the frame. The cover comprises a bioprosthetic tissue that can be regenerative or fixed and non-regenerative. The frame can be bioabsorbable or non-degradable. A ring prosthesis and a method of manufacturing a ring prosthesis is also provided. The ring prosthesis comprising an elongated rod member formed into a substantially ring shape, the elongated rod member being formed substantially from a flat bioprosthetic tissue.

Claims

1. An annuloplasty ring prosthesis comprising: a frame comprising an outer surface; and a cover surrounding the outer surface of the frame; wherein the cover comprises a bioprosthetic tissue.

2. The annuloplasty ring prosthesis of claim 1, wherein the bioprosthetic tissue is a fixed, non-regenerative bioprosthetic tissue.

3. The annuloplasty ring prosthesis of claim 2, wherein the fixed, non-regenerative bioprosthetic tissue is selected from the group consisting of: pericardium, blood vessels, skin, dura mater, small intestinal submucosa, ligaments, tendons, muscle, ureter, urinary bladder, liver, and heart.

4. The annuloplasty ring prosthesis of claim 3, wherein the fixed, non-regenerative bioprosthetic tissue is a pericardium.

5. The annuloplasty ring prosthesis of claim 2, wherein the fixed, non-regenerative bioprosthetic tissue is fixed with an aldehyde.

6. The annuloplasty ring prosthesis of claim 5, wherein the aldehyde is a glutaraldehyde.

7. The annuloplasty ring prosthesis of claim 5, wherein free aldehyde groups in the fixed, non-regenerative bioprosthetic tissue are subjected to a capping treatment comprising a capping agent.

8. The annuloplasty ring prosthesis of claim 7, wherein the capping agent comprises an amine.

9. The annuloplasty ring prosthesis of claim 8, wherein the capping treatment further comprises a reducing agent.

10. The annuloplasty ring prosthesis of claim 9, wherein the reducing agent is a borohydride.

11. The annuloplasty ring prosthesis of claim 2, wherein the fixed, non-regenerative bioprosthetic tissue is plasticized.

12. The annuloplasty ring prosthesis of claim 11, wherein the fixed, non-regenerative bioprosthetic tissue is plasticized with a polyol.

13. The annuloplasty ring prosthesis of claim 12, wherein the polyol is a glycerol.

14. The annuloplasty ring prosthesis of claim 1, wherein: the cover is formed as a sheet having a first edge and a second edge; the sheet covers the outer surface of the frame; and the first edge and the second edge are joined together to form a seam.

15. The annuloplasty ring prosthesis of claim 14, wherein: the sheet is dimensioned to permit the first edge and the second edge of the sheet to fold or roll upon each other to form a lip; and the lip protrudes away from the outer surface of the frame.

16. The annuloplasty ring prosthesis of claim 1, wherein the frame comprises one or both of a non-degradable polymer and a non-degradable metal or metal alloy.

17. The annuloplasty ring prosthesis of claim 16, wherein the frame comprises a non-degradable metal or metal alloy selected from the group consisting of: stainless steel, a nickel-based alloy, a cobalt-chromium alloy, a nickel-cobalt-chromium alloy, Nitinol, and combinations thereof.

18. The annuloplasty ring prosthesis of claim 1, wherein the bioprosthetic tissue is a regenerative bioprosthetic tissue.

19. The annuloplasty ring prosthesis of claim 18, wherein the regenerative bioprosthetic tissue is a decellularized biological tissue.

20. The annuloplasty ring prosthesis of claim 19, wherein the decellularized tissue is selected from the group consisting of: pericardium, blood vessels, skin, dura mater, small intestinal submucosa, ligaments, tendons, muscle, ureter, urinary bladder, liver, and heart.

21. The annuloplasty ring prosthesis of claim 19, wherein the regenerative bioprosthetic tissue is an artificial scaffold.

22. The annuloplasty ring prosthesis of claim 21, wherein the artificial scaffold is a biodegradable polymer scaffold.

23. The annuloplasty ring prosthesis of claim 22, wherein the biodegradable polymer scaffold comprises a polyglycolic acid.

24. The annuloplasty ring prosthesis of claim 21, wherein the artificial scaffold further comprises an extracellular matrix protein.

25. The annuloplasty ring prosthesis of claim 24, wherein the extracellular matrix protein is one or more proteins selected from the group consisting of: hydroxyproline, vitronectin, fibronectin, collagen I, collagen III, collagen IV, collagen VI, collagen XI, collagen XII, fibrillin I, tenascin, decorin, byglycan, versican, asporin, agrin, and combinations thereof.

26. The annuloplasty ring of claim 2, wherein the frame is bioabsorbable.

27. The annuloplasty ring prosthesis of claim 26, wherein the bioabsorbable frame comprises a metal or a metal alloy.

28. The annuloplasty ring prosthesis of claim 27, wherein the metal or the metal alloy comprises one or a combination selected from the group consisting of magnesium, aluminum, iron, and zinc.

29. The annuloplasty ring prosthesis of claim 27, wherein: the metal or the metal alloy has an ultimate tensile strength of about 30 MPa to about 400 MPa; and the metal or the metal alloy has an elongation of about 0.3 percent to about 170 percent.

30. The annuloplasty ring prosthesis of claim 26, wherein the bioabsorbable frame is one or a combination of polymers selected from the group consisting of: poly(L-lactide), poly(D-lactide), polyglycolide, poly(L-lactide-co-glycolide), polyhydroxyalkonate, polysaccharides, polyesters, polyhydroxyalkanoates, polyalkelene esters, polyamides, polycaprolactone, polylactide-co-polycaprolactone, polyvinyl esters, polyamide esters, polyvinyl alcohols, modified derivatives of caprolactone polymers, polytrimethylene carbonate, polyacrylates, polyethylene glycol, terminal dials, poly(L-lactide-co-trimethylene carbonate), polyhydroxybutyrate, polyhydroxyvalerate, poly-orthoesters, poly-anhydrides, polyiminocarbonate, and copolymers.

31. The annuloplasty ring prosthesis of claim 26, wherein the bioabsorbable frame is reinforced with magnesium or a magnesium alloy.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0046] FIG. 1A is a top plan view of a mitral annuloplasty ring in accordance with one example.

[0047] FIG. 1B is a side view of the annuloplasty ring shown in FIG. 1A.

[0048] FIG. 1C is a cross-sectional view of the annuloplasty ring shown in FIG. 1A, taken along the lines 1C-1C of FIG. 1A.

[0049] FIG. 1D is a perspective cross-sectional view of an alternative example of the mitral annuloplasty ring shown in FIG. 1A.

[0050] FIGS. 1E and 1F are cross-sectional views of alternative examples of the mitral annuloplasty ring shown in FIG. 1A.

[0051] FIG. 2 is a top plan view of a sheet of bioprosthetic tissue in accordance with another example.

[0052] FIG. 3A is a top plan view of a tricuspid annuloplasty ring in accordance with another example.

[0053] FIG. 3B is a side view of the annuloplasty ring shown in FIG. 3A.

[0054] FIG. 3C is a cross-sectional view of the annuloplasty ring shown in FIG. 3A, taken along the lines 3C-3C of FIG. 3A.

[0055] FIG. 3D is a cross-sectional view of the annuloplasty ring shown in FIG. 3A, taken along the lines 3D-3D of FIG. 3A.

[0056] FIGS. 3E and 3F are cross-sectional views of alternative examples of the tricuspid annuloplasty ring shown in FIG. 3A.

[0057] FIG. 4A is a partially-exploded perspective view of a sewing ring and a prosthetic heart valve in accordance with another example.

[0058] FIG. 4B is a top perspective view of the prosthetic heart valve and sewing ring shown in FIG. 4A.

[0059] FIG. 5A is a perspective view a substantially flat biological tissue having opposing surfaces.

[0060] FIG. 5B is a perspective view of the rolling of the substantially flat biological tissue of FIG. 5A.

[0061] FIG. 5C is a perspective view the rolled, substantially flat biological tissue of FIG. 5A.

[0062] FIG. 5D is a perspective view of the rolled, substantially flat biological tissue of FIG. 5C having its free edge sutured.

[0063] FIG. 5E is a perspective view of the rolled, substantially flat biological tissue of FIG. 5D with its free edge sutured and its two ends cut off.

[0064] FIG. 6 is a perspective view of an annuloplasty ring having a discontinuous or C-shaped periphery in accordance with another example.

[0065] FIG. 7 is a perspective view of an annuloplasty ring having a continuous periphery in accordance with another example.

[0066] FIG. 8A is a cross-sectional view of the annuloplasty ring shown in FIG. 6 or 7, taken along the lines 8A-8A of FIG. 7.

[0067] FIGS. 8B-8C are alternative cross-sectional views of embodiments of the annuloplasty ring shown in FIG. 6 or 7.

DETAILED DESCRIPTION OF SOME EXAMPLES

[0068] With reference to FIGS. 1A-1F and 3A-3F of the illustrative drawings, there are shown examples of annuloplasty rings 100. The annuloplasty ring 100 can be suitable for annulus of a valve, such as the mitral annulus (FIGS. 1A-1F) or the tricuspid annulus (FIGS. 3A-3F).

[0069] FIGS. 1A-1F illustrate examples of a mitral annuloplasty ring 100 having a continuous or D-shaped periphery. The mitral annuloplasty ring 100 can be shaped to closely mimic the geometry of a healthy mitral annulus, and can be configured to minimize the likelihood of dehiscence while maintaining the shape of a healthy valve annulus.

[0070] FIGS. 3A-3F illustrate examples of a tricuspid annuloplasty ring 100, with a discontinuous or C-shaped periphery, including two free ends 133 that define a gap therebetween. The tricuspid annuloplasty ring 100 can be shaped to closely mimic the geometry of a healthy tricuspid annulus, and can be configured to minimize the likelihood of dehiscence while maintaining the shape of a healthy valve annulus. The tricuspid annuloplasty ring 100 is not complete in about ten percent of the circumference around the anteroseptal commissure of the tricuspid annulus. This is to prevent suture injury to the conduction system. With particular reference to FIG. 3B, the tricuspid annuloplasty ring 100 can have a somewhat spiral shape that mimics the shape of a healthy tricuspid annulus.

[0071] In one example, the two free ends 133 are separated at a distance to define a gap therebetween. The distance between the two free ends 133 can be about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50% of a length of the tricuspid annuloplasty ring 100, or in a range that includes and is between any two of the foregoing values.

[0072] In one example, the two free ends 133 can be coplanar with the frame 110. In another example, one of the two free ends 133 can be offset from the other one of the free ends 133. The two free ends 133 can be vertically offset from one another at a distance that is about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 35%, about 40%, about 45%, about 50% of a length of the tricuspid annuloplasty ring 100, or in a range that includes and is between any two of the foregoing values.

[0073] The annuloplasty ring 100 can comprise a frame 110 having an outer surface 120, and a cover 130 surrounding the frame 110. The cover 130 comprises a bioprosthetic tissue. In some examples, the bioprosthetic tissue can be fixed and non-regenerative. In other examples, the bioprosthetic tissue can be regenerative.

[0074] The term “regenerative” as it relates to bioprosthetic tissue is understood to mean tissue that permits or even stimulates ingrowth of host cells and tissue into the bioprosthetic tissue after implantation. Thus, “regenerative tissue” can include three-dimensional scaffolds that support the ingrowth of host cells and tissue. In one example, the regenerative tissue can remain after in-growth of host cells and tissue. In another example, the regenerative tissue can partially or completely biodegrade after in-growth of host cells and tissue.

[0075] For the fixed and non-regenerative examples, the bioprosthetic tissue can be selected from the group consisting of: pericardium, blood vessels, skin, dura mater, small intestinal submucosa, ligaments, tendons, muscle, ureter, urinary bladder, liver, and heart. For example, the fixed, non-regenerative bioprosthetic tissue can be a pericardium. In one example, the fixed, non-regenerative bioprosthetic tissue can be fixed with an aldehyde such as a glutaraldehyde. In another example, the free aldehyde groups in the fixed, non-regenerative bioprosthetic tissue can be subjected to a capping treatment comprising a capping agent. In a one example, the capping treatment can comprise an amine. In an additional example, the capping treatment can further comprise a reducing agent such as a borohydride. In one example, the fixed, non-regenerative bioprosthetic tissue can be plasticized. In another example, the fixed, non-regenerative bioprosthetic tissue can be plasticized with a polyol such as a glycerol.

[0076] In one example, the bioprosthetic tissue can be subjected to a fixation or cross-linking treatment, as a result of which the bioprosthetic tissue is rendered less antigenic and is at least partially or completely cross-linked. The fixation process can also render the tissue non-regenerative. The fixation process is understood to include any chemical, heat or other processes, as a result of which the bioprosthetic tissue is preserved and rendered mechanically and dimensionally stable.

[0077] The fixation process can include contacting the tissue with one or more fixatives. Known fixatives include aldehydes, polyaldehydes, diisocyanates, carbodiimides, photo-oxidation agents, and polyepoxide compounds. In a preferred example, the fixative used is glutaraldehyde. Glutaraldehyde-fixed tissue, however, is particularly vulnerable to calcification since glutaraldehyde fixation results in the generation of residual aldehyde groups and labile Schiff bases. The residual aldehydes and Schiff bases can be potential binding sites for calcium. The aldehyde groups can oxidize to carboxylic acid groups, which are known to attract and bind calcium.

[0078] Various techniques have therefore been developed to reduce the aldehyde and acid levels of glutaraldehyde-fixed tissues, and thus reduce its propensity to calcify after implantation in the patient.

[0079] The fixation process can include adjusting the pH of the glutaraldehyde fixative in solution to reduce the generation of calcium binding sites, as disclosed in U.S. Pat. No. 6,878,168 to Edwards Lifesciences, the entire contents of which are incorporated into this description by reference. In a preferred example, the pH of the glutaraldehyde fixative in solution is about or provided in a range including and between any two of the following pH values: 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, and 9.

[0080] The fixation process can also further include the addition of a heat-treating step after contacting with the one or more fixatives. Glutaraldehyde-fixed tissue have demonstrated a reduced aldehyde and carboxylic acid content after heat treatment, and thus a marked reduction in calcification after implantation, as compared to glutaraldehyde-fixed tissue without heat treatment. The glutaraldehyde fixative in solution can be heat treated before, during, or after the bioprosthetic tissue is immersed in the solution. The heat treatment can include heating the glutaraldehyde fixative in solution to a temperature provided in a range including and between any two of the following temperatures: 40° C., 41° C., 42° C., 43° C., 44° C., 45° C., 46° C., 47° C., 48° C., 49° C., 50° C., 51° C., 52° C., 53° C., 54° C., 55° C., 56° C., 57° C., 58° C., 59° C., 60° C., 61° C., 62° C., 63° C., 64° C., 65° C., 66° C., 67° C., 68° C., 69° C., 70° C., 71° C., 72° C., 73° C., 74° C., 75° C., 76° C., 77° C., 78° C., 79° C., and 80° C. Exemplary processes for heat treating glutaraldehyde-fixed tissue are described in U.S. Pat. No. 6,561,970, issued May 13, 2003 to Edwards Lifesciences, the entire contents of which are incorporated into this description by reference. The heat treatment of glutaraldehyde-fixed tissue is also commercially known as the Carpentier-Edwards ThermaFix® (TFX) tissue treatment process from Edwards Lifesciences.

[0081] Following or concurrently with the fixation process, the bioprosthetic tissue can be subjected to a capping treatment that comprises a capping agent, a reducing agent, or both. The bioprosthetic tissue can include functional groups that exist either inherently in the bioprosthetic tissue, as a result of being cross-linked or fixed, or as a result of being subjected to any number of chemical or physical processes, including the pre-conditioning, pre-stressing, or pre-damaging processes disclosed in this description. Exemplary processes for treatment with capping and reducing agents are described in U.S. Pat. No. 7,972,376, the entire contents of which are incorporated into this disclosure by reference.

[0082] In one example, the bioprosthetic tissue can be subjected to a capping treatment without the step of fixing or crosslinking the bioprosthetic tissue. In another example, the bioprosthetic tissue can be subjected to the capping treatment before, during, or after the step of fixing or crosslinking the bioprosthetic tissue.

[0083] In one example, the capping agent can include any one or a combination of the following: an amine, such as an alkyl amine, amino alcohols and ethanolamine; an amino acid, such lysine and hydroxylysine; an amino sulfonate, such as taurine, amino sulfates, dextran sulfate, and chondroitin sulfate; hydrophilic multifunctional polymers, such as polyvinyl alcohols and polyethyleneimines; a hydrophobic multifunctional polymer; α-dicarbonyls, including methylglyoxal, 3-deoxyglucosone, and glyoxal; hydrazines, such as adipic hydrazide; disuccinimidyl N,N-carbonate; carbodiimides, such as 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC), N-cyclohexyl-N′-(2-morpholinoethyl)carbodiimide (CMC), and 1,3-dicyclohexyl carbodiimide (DCC); and 2-chloro-1-methylpyridinium iodide (CMPI).

[0084] In another example, the capping agent can be any agent that is reactive with a functional group, wherein the functional group is a free aldehyde or a free carboxylic acid. The capping agent can be an amine, such as an alkyl amine or an amino alcohol. The capping agent can be an ethanolamine.

[0085] In a further example, the capping agent can be any agent that is reactive with a functional group, wherein the functional group is an amine, a hydroxyl, or a sulfhydryl group. In accordance with this example, the capping agent can comprise a carbonyl functional group. The carbonyl functional group can be an aldehyde or a carboxylic acid and can be selected from a monoaldehyde, a polyaldehyde, a monocarboxylic acid, a polycarboxylic acid, and the like.

[0086] Regardless, certain reactions of the capping agent and functional groups can produce labile Schiff bases and it can be desirable to reduce the Schiff bases and replace them with a more stable amine.

[0087] Accordingly, the capping treatment of the bioprosthetic tissue can further include treatment with a reducing agent. The reducing agent can be selected to reduce Schiff bases formed from the reaction of the crosslinking agent and the bioprosthetic tissue, the capping agent and the bioprosthetic tissue, and the capping agent and the crosslinking agent. In one example, the bioprosthetic tissue can be treated with the reducing agent, with or without the fixing or crosslinking the bioprosthetic tissue. In another example, the bioprosthetic tissue can be treated with the reducing agent, with or without the capping agent. In a further example, the bioprosthetic tissue can be treated with the reducing agent, with or without both the fixing or crosslinking and capping the bioprosthetic tissue.

[0088] The reducing agent can be any one or a combination of agents that comprise a borohydride. In one example, the reducing agent can be one or a combination selected from the group consisting of sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride, sodium bisulfate in acetylacetone, formic acid in formaldehyde, alkyl borohydride, amino borohydride, lithium aminoborohydrides, and an organoborate hydride salt having the formula XBR.sub.3H, where R is an alkyl group and X is lithium, sodium, or potassium. The lithium aminoborohydride can be a lithium dimethylaminoborohydride, a lithium morpholinoborohydride, and a lithium pyrrolidinoborohydride, to name a few. The organoborate hydride salt reducing agent can be a lithium tri-sec-butyl(hydrido)borate, a sodium tri-sec-butyl(hydrido)borate, a potassium tri-sec-butyl(hydrido)borate, or a lithium aluminum hydride.

[0089] The bioprosthetic tissue can be subjected to a capping treatment in which it is treated with a capping agent and a reducing agent in a solution. In one example, the capping agent is selected to react with one or more functional groups associated with the bioprosthetic tissue and the reducing agent is selected to reduce Schiff bases. The Schiff bases can be formed from any one or more of the reaction of the crosslinking agent and the bioprosthetic tissue, the reaction of the capping agent and the bioprosthetic tissue, and the reaction of the capping agent and the crosslinking agent. The capping agent can be an amine or an amino alcohol, such as an ethanolamine; the functional groups can be an aldehyde or a carboxylic acid; the reducing agent can be a borohydride, such as a sodium borohydride; and the crosslinking agent can be an aldehyde-containing agent, such as a glutaraldehyde. The capping treating can be performed sequentially with first the capping agent and then the reducing agent in solution or simultaneously with both the capping and reducing agents present in the solution. In one example, the capping treating can be performed with the capping agent and reducing agent in a solution on an orbital shaker operating at about 80 to about 100 rpm for about 4 hours.

[0090] Exemplary methods for treating bioprosthetic tissue with capping and reducing agents are described in U.S. Pat. No. 7,972,376, issued Jul. 5, 2011 to Edwards Lifesciences Corp., the entire contents of which are incorporated into this disclosure by reference for all purposes.

[0091] The capping treatment can comprise a capping agent, a reducing agent, or both. The capping treatment can be performed after the fixed bioprosthetic tissue has been subjected to a process of pre-conditioning, pre-stressing, or pre-damaging to generate additional acid binding sites, which can subsequently be capped, as described in U.S. Patent Application Publication No. 2008/0302372, published Dec. 11, 2008, entitled “Methods for Pre-Stressing and Capping Bioprosthetic Tissue” to Edwards Lifesciences, the entire contents of which are incorporated into this disclosure by reference for all purposes. In one example, the bioprosthetic tissue can be subjected to a rapid pulsed fluid flow (in the range of about 4 Hz to about 1,500 Hz), repeated flexion of the bioprosthetic tissue valve, elevated temperature (in the range of about 26° C. to about 65° C.), an acidic solution (pH in the range of about 4 to about 7), alkaline solution (pH in the range of about 8 to about 10), or any combination of the foregoing for the purpose of generating additional acid binding sites, which can be capped, reduced, or both, in a separate treatment process.

[0092] The bioprosthetic tissue can further undergo treatment with anhydrous, non-aqueous, or aqueous solutions to substantially, if not completely, dehydrate the bioprosthetic tissue for dry storage. The bioprosthetic tissue following glycerol treatment can contain residual water or moisture within the tissue interstices but can be packaged for dry storage.

[0093] In one example, the bioprosthetic tissue can be treated with an anhydrous, non-aqueous, or aqueous solution that comprises glycerol. In one example, the anhydrous, non-aqueous, or aqueous solution can comprise about 25% by volume, 30% by volume, 35% by volume, 40% by volume, 45% by volume, 50% by volume, 55% by volume, 60% by volume, 65% by volume, 70% by volume, 75% by volume, 80% by volume, 85% by volume, 90% by volume, or 95% by volume glycerol. In another example, the anhydrous, non-aqueous, or aqueous solution comprises an amount of glycerol within and including any two of the foregoing values.

[0094] In another example, the anhydrous, non-aqueous, or aqueous glycerol solution can comprise alcohol. In one example, the anhydrous, non-aqueous, or aqueous solution can comprise about 5% by volume, about 10% by volume, about 15% by volume, about 20% by volume, about 25% by volume, about 30% by volume, about 35% by volume, about 40% by volume, about 45% by volume, about 50% by volume, about 55% by volume, about 60% by volume, about 65% by volume, about 70% by volume, or about 75% by volume alcohol. In another example, the anhydrous, non-aqueous, or aqueous solution comprises an amount of alcohol within and including any two of the foregoing values. The alcohol can be any one or a combination of C.sub.1, C.sub.2, C.sub.3, C.sub.4, and C.sub.5 alcohols, such as ethanol, propanol, and butanol.

[0095] In one example, the solution is a non-aqueous solution of about 75% by volume glycerol and 25% by volume ethanol. The bioprosthetic tissue is immersed in the solution for a period of time sufficient to permit the solution to permeate the bioprosthetic tissue. The bioprosthetic tissue is then removed from the solution to allow removal of excess solution. Suitable treatment for the bioprosthetic tissues is described in U.S. Pat. No. 8,007,992, issued Aug. 30, 2011, to Edwards Lifesciences Corp., the entire contents of which are incorporated into this disclosure by reference for all purposes.

[0096] In another preferred example, an aqueous glycerol solution can be used to at least partially dehydrate the tissue, as described in U.S. Pat. No. 6,534,004, issued Mar. 18, 2003, issued to The Cleveland Clinic Foundation, the entire contents of which are incorporated into this disclosure by reference for all purposes.

[0097] The bioprosthetic tissue can also be treated by means other than the glycerol treatment process described above to dry or dehydrate the bioprosthetic tissue. The terms “dry” or “dehydrate,” as used in this disclosure with reference to the bioprosthetic tissue or the implantable bioprosthetic device, is understood to include residual water or moisture that can be present in the bioprosthetic tissue following glycerol or other treatment to reduce the water content of the bioprosthetic tissue. In one example, the water content of the dried or dehydrated bioprosthetic tissue following glycerol or other treatment is about 25% by weight or less, about 20% by weight or less, about 15% by weight or less, about 10% by weight or less, about 9% by weight or less, about 8% by weight or less, about 7% by weight or less, about 6% by weight or less, about 5% by weight or less, about 4% by weight or less, about 3% by weight or less, about 2% by weight or less, or about 1% by weight or less. These percentages are understood to be based on the combined weight of the bioprosthetic tissue and water content.

[0098] For the regenerative examples, the bioprosthetic tissue can be an artificial or biological scaffold or a decellularized biological tissue. For example, the bioprosthetic tissue can be selected from the group consisting of: pericardium, blood vessels, skin, dura mater, small intestinal submucosa, ligaments, tendons, muscle, ureter, urinary bladder, liver, and heart. It is understood that the tissue selected is decellularized using any suitable method.

[0099] In one example, the regenerative bioprosthetic tissue can be an artificial scaffold. In another example, the artificial scaffold can be a biodegradable polymer scaffold. A biodegradable polymer can include a polymer in which the bonds of the polymer-chain cleave, primarily by aqueous hydrolysis as a result of contact with blood and other bodily fluids at physiological pH (e.g., around 7 to 7.5). This process results in the fragmentation and eventual decomposition of the polymer in vivo. The fragmentation and decomposition process can be catalyzed by enzymes or other endogenous biological compounds. In a further example, the biodegradable polymer scaffold can comprise a polyglycolic acid. In an additional example, the artificial scaffold can further comprise one or more extracellular matrix proteins. For example, the extracellular matrix protein can be one or more proteins selected from the group consisting of: hydroxyproline, vitronectin, fibronectin, collagen I, collagen III, collagen IV, collagen VI, collagen XI, collagen XII, fibrillin I, tenascin, decorin, byglycan, versican, asporin, agrin, and combinations thereof.

[0100] In some examples, the cover 130 can be formed from a sheet 134 of bioprosthetic tissue (FIG. 2). The sheet 134 can have a first edge 131 and a second edge 132. With reference to FIGS. 1C and 3C, the sheet 134 can cover the outer surface 120 of the frame 110, and the first edge 131 and the second edge 132 can be sewn, glued, or otherwise joined together to form a seam 136. In some examples of a tricuspid annuloplasty ring 100 (FIGS. 3A-3D), the sheet 134 can extend beyond the frame 110 to form an enlarged region of covering 130 at the free ends (FIG. 3D).

[0101] The glue used to form and shape the cover 130, such as joining the first and second edges 131, 132, is preferably one that is biocompatible and strongly bonds tissue in a wet environment (e.g., flowing blood). In one example, the glue is a hydrophobic light-activated adhesive (HLAA). The HLAA can be formed by combining a poly(glycerol sebacate acrylate) (PGSA) with a photo-initiator, such as 2-hydroxy-1-[4-(2-hydroxyethoxy)phenyl]-2-methyl-1-propanone) (IRGACURE 2959, Sigma-Aldrich) to create the HLAA. The HLAA can be a thick gel that can be applied onto the cover and then cross-linked by ultraviolet light. The resulting bond is preferably water-tight yet flexible and stays intact in the face of high pressure and flowing blood.

[0102] With reference to FIGS. 1A, 1B, 3A, and 3B, the cover 130 can comprise a plurality of sheets 134 that abut each other at part-interface seams 137. In some examples, the part-interface seams 137 can define markings to aid a surgeon with correct positioning of the ring 100 on the valve anulus. With reference to FIG. 1D, in some examples, the sheet 134 can be dimensioned to permit the first edge 131 and the second edge 132 of the sheet to fold or roll upon each other to form a lip 138. In further examples, the lip 138 can protrude away from the outer surface 120 of the frame 110.

[0103] The outer cover 130 comprising a bioprosthetic tissue can encourage native tissue growth on the annuloplasty ring 100, which can help to maintain the ring 100 in place on the valve annulus. In addition, bioprosthetic-tissue cover 130 can be used in patients with endocarditis or in patients who are otherwise intolerant of cloth-covered implants.

[0104] As discussed above, the cover 130 is wrapped around a frame 110. In some examples, the frame 110 can be bioabsorbable. In other examples, the frame no can be non-degradable.

[0105] For the non-degradable examples, the frame 110 can comprise one or both of a non-degradable polymer and a non-degradable metal or metal alloy. For example, in one example, the frame no can comprise a non-degradable metal or metal alloy selected from the group consisting of: stainless steel, a nickel-based alloy, a cobalt-chromium alloy, a nickel-cobalt-chromium alloy, nitinol, and combinations thereof.

[0106] For the bioabsorbable examples, the bioabsorbable frame no can comprise a degradable metal or a metal alloy. For example, the degradable metal or metal alloy can comprise one or a combination selected from the group consisting of: magnesium, aluminum, iron, and zinc. The metal or metal alloy can have an ultimate tensile strength of about 30 MPa to about 400 MPa and an elongation of about 0.3 percent to about 170 percent.

[0107] In one example, the bioabsorbable frame no can be a bioabsorbable material. For example, the bioabsorbable material can be one or a combination of polymers selected from the group consisting of: poly(L-lactide), poly(D-lactide), polyglycolide, poly(L-lactide-co-glycolide), polyhydroxyalkonate, polysaccharides, polyesters, polyhydroxyalkanoates, polyalkelene esters, polyamides, polycaprolactone, polylactide-co-polycaprolactone, polyvinyl esters, polyamide esters, polyvinyl alcohols, modified derivatives of caprolactone polymers, polytrimethylene carbonate, polyacrylates, polyethylene glycol, terminal dials, poly(L-lactide-co-trimethylene carbonate), polyhydroxybutyrate, polyhydroxyvalerate, poly-orthoesters, poly-anhydrides, polyiminocarbonate, and copolymers.

[0108] In another example, the bioabsorbable frame no can be reinforced with a reinforcing composition. For example, in one example, the reinforcing composition can comprise magnesium or a magnesium alloy.

[0109] While the frame no is shown to have a circular cross-section in FIGS. 1C, 1D, and 3C, it should be understood that the frame no can have other cross-sectional shapes and thicknesses. For example, in some examples, the frame no can have a rounded semi-circular or even polygonal cross-section. In other examples, the shape or thickness of the frame no can be uniform across the periphery of the ring 100 or it can vary across the periphery of the ring 100.

[0110] In some examples, the ring 100 can further include a suture-permeable interface 140 having one or more layers between the frame 110 and the cover 130. For instance, the suture-permeable interface can comprise an elastomeric sleeve (FIGS. 1F and 3F) such as a silicone rubber molded around the frame 110. The elastomeric sleeve can provide bulk to the ring for ease of handling and implant, and permit passage of sutures though not significantly adding to the anchoring function of the outer cover 130. In one example, the suture-permeable interface 140 can be provided around at least a portion of the periphery of the ring 100 (FIGS. 1E and 1F). In another example, the suture-permeable interface 140 can be provided around the entire periphery of the ring 100.

[0111] With reference now to FIGS. 4A and 4B of the illustrative drawings, there is shown a sewing ring 200 for a prosthetic heart valve 300. The prosthetic heart valve 300 can comprise a support frame 310 defining an orifice 320 about an axis A along an inflow-outflow direction. A plurality of leaflets 330 can be mounted for movement on the support frame 310 to provide a one-way valve 340 in the orifice 320. Each of the plurality of leaflets 330 can comprise the bioprosthetic tissue described above.

[0112] The sewing ring 200 can be connected to and positioned around the support frame 310 for attaching the heart valve 300 to a valve annulus (not shown). The sewing ring 200 can include a suture-permeable annular member 210 comprising an outer surface 220, and a cover 230 surrounding the annular member 210.

[0113] The cover 230 comprises the bioprosthetic tissue described above. For example, as previously outlined, the cover 230 can comprise bioprosthetic tissue that is fixed and non-regenerative, or bioprosthetic tissue that is regenerative. In either case, the cover 230 is wrapped around the annular member 210, which can be molded from a suture-permeable, biocompatible polymer such as silicone. In one example, the annular member 210 can comprise a molded polymer selected from the group consisting of: silicone, polyurethane, and combinations thereof. As with the cover 130 for the annuloplasty ring 100, the cover 230 for the sewing ring 200 can be formed from a sheet 134 of bioprosthetic tissue (FIG. 2), as discussed above.

[0114] In one example, the cover 230 and the plurality of leaflets 330 are made from the same bioprosthetic tissue.

[0115] With reference to FIGS. 5A-5E of the illustrative drawings, there is shown a method of manufacturing various embodiments of ring protheses which includes annuloplasty rings and sewing rings, including those depicted in FIGS. 6 and 7. As with the annuloplasty rings described herein, ring protheses fabricated in accordance with the depicted method can be suitable for the annulus of a valve, such as the tricuspid annulus (FIG. 6) or the mitral annulus (FIG. 7). Additionally, ring protheses fabricated in accordance with the depicted manner can be used in fabricating a prosthetic heart valve, as shown in FIGS. 4A-4B.

[0116] FIG. 5A depicts an example of a bioprosthetic tissue 500 having a length L and a width W. The bioprosthetic tissue 500 can comprise two opposing surfaces: a first surface 504 and a second surface 502. In one embodiment, the first surface 504 can have a rough texture or can be fibrous and the second surface 502 can be smoother than the first surface 504. Certain biological tissues can be characterized as having such surfaces, such as pericardial tissue and dura mater. These tissues are covered by a cell surface layer only on one side and thus have a smooth and even surface on this side while the opposing side is rough and fibrous. For purposes of cellular integration and infiltration by the host, the rough side can provide a suitable surface.

[0117] While FIG. 5A depicts a perfectly rectilinear shape, it is understood that the biological tissue 500 can be of any shape of a defined length and width so long as it can provide the desired diameter of the resulting ring prosthesis. FIGS. 5B-5C depict one example of how the biological tissue 500 can be rolled upon itself to produce an elongated rod member 510 having a free edge 506 between the first and second secured ends 501A and 501B. While FIGS. 5A and 5B depict the elongated rod member 510 as has having a substantially cylindrical cross-sectional shape (FIG. 8A), it is understood that the biological tissue 500 can be rolled or folded in a manner to produce other cross-sectional shapes, such as a triangular cross-sectional shape (FIG. 8C). Alternatively, the elongated rod member 510 can be formed into a rectilinear cross-sectional shape by alternating folds in an accordion-style (FIG. 8B).

[0118] The elongated rod body 510 can be secured at its first and second secured ends 501A, 501B by wrapping with a string or suture 50 so that it may retain its substantially cylindrical shape. Once the first and second ends 501A, 501B are secured, the free edge 506 can be secured to the rod body 510. While FIG. 5D depicts the free edge 506 being secured to the rod body 510 with sutures 60, it is understood that the free edge 506 can be secured with any biocompatible substance, such as the adhesives described herein.

[0119] As shown in FIGS. 5E and 6, the free edge 506 may be sutured in such a manner to impart a curvature to the shape of the rod body 510. The two free ends 500A and 500B can be separated at a distance d to define a gap therebetween to produce an open ring 540 as depicted in FIG. 6. The distance D between the two free ends 500A and 500B can be about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50% of a length of the rod body 510, or in a range that includes and is between any two of the foregoing values. Once the free edge 506 is sutured, the first and second secured ends 501A, 501B can be cut off to produce first and second free ends 500A and 500B. The resulting rod body 510 can consist only of the biological tissue 500 and the sutures 60 which can be made of a dissolvable or bioabsorbable material.

[0120] In one example, the two free ends 500A and 500B can be coplanar with the rod body 510. In another example, one of the two free ends 500A, 500B can be offset from the other one of the free ends. The two free ends 500A, 500B can be vertically offset from one another at a distance that is about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 35%, about 40%, about 45%, about 50% of a length of the ring prosthesis, or in a range that includes and is between any two of the foregoing values.

[0121] In another example, the two free ends 500A, 500B can be joined together to produce an enclosed ring 550 as depicted in FIG. 7. In one example, the two free ends 500A, 500B can be sutured together to produce a seam 512 therebetween.

[0122] It is understood that the bioprosthetic tissue can be treated in any manner as described above either before or after it is formed into a ring prosthesis.

[0123] It should be appreciated from the foregoing description that the present disclosure provides improved ring prostheses, including annuloplasty rings and sewing rings that can encourage native tissue growth around the implant, to help maintain the implants in place, and that can be used in patients with endocarditis or in patients who or otherwise intolerant of cloth-covered implants.

[0124] Specific methods, devices, and materials are described, although any methods and materials similar or equivalent to those described can be used in the practice or testing of the present example. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this example belongs. The terms “a,” “an,” and “at least one” encompass one or more of the specified element. That is, if two of a particular element are present, one of these elements is also present and thus “an” element is present. The terms “a plurality of” and “plural” mean two or more of the specified element. The term “or” used between the last two of a list of elements means any one or more of the listed elements. For example, the phrase “A, B, or C” means “A, B, and/or C,” which means “A,” “B,” “C,” “A and B,” “A and C,” “B and C,” or “A, B, and C.” The term “coupled” generally means physically coupled or linked and does not exclude the presence of intermediate elements between the coupled items absent specific contrary language.

[0125] Without further elaboration, it is believed that one skilled in the art, using the proceeding description, can make and use the disclosed subject matter to the fullest extent. The subject matter has been described in detail with reference only to the presently preferred examples. Persons skilled in the art will appreciate that various modifications can be made without departing therefrom. Accordingly, the scope is defined only by the following claims.